I think you are referring to ADE (antibody dependent enhancement). This is a function of the vaccine, not the virus. The idea here it to use a strain you know is safer than one you know is more dangerous.
For a challenge trial you only need enough virus for a few thousand people at most. It is not difficult to produce this amount of virus in cell culture.